Effects of an XXXX -Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung Cancer.

@entity1 @entity75 @entity5 @entity470 @entity1149
OBJECTIVE: This study was aimed at optimizing the treatment of @entity1149 ( @entity1149 ) @entity1 who are candidates for stereotactic radiosurgery (SRS) for brain metastases and harbor activating @entity470 ( @entity470 ) mutations. METHODS: We retrospectively reviewed the medical records from 2005 to 2010 of @entity1149 @entity1 with brain metastases harboring an activating @entity470 mutation. @entity1 who received a combination therapy of SRS and @entity470 -tyrosine kinase inhibitor (TKI) for brain metastases and those who received SRS without @entity470 -TKI were compared. The primary endpoint was progression-free survival (PFS) of the brain metastases. RESULTS: Thirty-one @entity1 were eligible for enrolment in this study (SRS with TKI, 18; SRS without TKI, 13). Twenty-two @entity1 (71.0%) were @entity1 and the median overall age was 56.0 years. PFS of @entity75 was not significantly prolonged in SRS with TKI treatment group than in SRS without TKI group (17.0 months vs. 9.0 months, p=0.45). @entity5 control rate was 83.3% in the combination therapy group, and 61.5% in the SRS monotherapy group (p=0.23). There were no severe adverse events related with treatment in both groups. CONCLUSIONS: Therapeutic outcome of concurrent SRS and TKI treatment was not superior to SRS monotherapy, however, there was no additive adverse events related with combined treatment.
